Trial
NCT04795869
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Seagen Inc.
Condition
Recurrent Angioimmunoblastic T-Cell Lymphoma
Intervention
Brentuximab Vedotin
Why stopped
Study inactivated due to zero accruals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-10